Intellectual property

Rise of New CRISPR Inventions: the toolbox of research applications for CRISPR-based systems continues to expand

Daniel Lim

Although much of the reporting around CRISPR tends to focus on its cleavage based ability to knock out or repair targeted sequences of DNA in a genome, some of the most exciting developments in the CRISPR field do not involve gene editing at all. Many of these advances are already being put into effect in Read More

French IPO allows extension of the duration of SPCs on the basis of the MA notification date

Laëtitia Bénard

The French Intellectual Property Office (IPO) recently issued a notice (French language) advising that the expiration date of French supplementary protection certificates (SPC) can be extended upon request of the registered SPC holder. The notice applies the 2015 Seattle Genetics ruling of the European Court of Justice (ECJ) which held that the relevant date for the Read More

China: Update on IP and regulatory developments

David Shen

The Chinese Food and Drug Administration (CFDA) recently released a number of new guidelines and regulations to implement the directives from the Central Government Opinion released on 8 October 2017 (see our earlier post: Chinese medicinal product approval reform announced). These new guidelines and regulations represent the efforts made by CFDA to promote innovation in the Chinese Read More

UK Court of Appeal asks the CJEU when Markush claims will be sufficiently specific for Article 3(a) of the SPC Regulation

Steven Baldwin

The Appellants in this action, Sandoz and Hexal, are appealing Arnold J’s decision to uphold SPC/GB07/038 on the basis that the Markush formulae in the basic patent are sufficient to satisfy the requirements of Article 3(a) of the SPC Regulation (Regulation (EC) No 469/2009). We have previously commented on the facts here and the first Read More

Broad Institute CRISPR-Cas9 patent revoked in Europe

Daniel Lim

Yesterday, the Opposition Division (OD) of the European Patent Office (EPO) has revoked one of the Broad Institute’s foundational CRISPR-Cas9 patents in Europe (EP2771468), upholding the preliminary opinion, which also found all claims of the patent to be invalid. The revocation of the patent will be suspended pending the completion of the appeal process, which the Broad Read More